Recent studies have demonstrated that β-adrenergic signaling enhances tumor growth through β2-adrenoreceptors (β2-ARs), and that propranolol administration (β1- and β2-AR antagonist) provides protection against different types of cancer [9,10,11]. Here, ADRB2 is linked to neoplasm.